Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Demonstration of Pharmacodynamic Equivalence of Enoxaparin Rovi (100-mg Subcutaneous Injection) to Clexane® (100-mg Subcutaneous Injection) in Healthy Volunteers

NCT03363477 is registered in ClinicalTrials.gov with Rovi Pharmaceuticals Laboratories as lead sponsor.

NCT NCT03363477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03363477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Demonstration of Pharmacodynamic Equivalence of Enoxaparin Rovi (100-mg Subcutaneous Injection) to Clexane® (100-mg Subcutaneous Injection) in Healthy Volunteers
Lead sponsor
Rovi Pharmaceuticals Laboratories
Phase
Phase 1
Overall status
Completed
Start date
September 25, 2015
Completion date
December 1, 2015
Enrollment
46 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy